Bioqual Inc BIOQ:OTCPK

*Data is delayed | Exchange | USD
Last | 03/12/24 EDT
80.00UNCH (UNCH)
52 week range
59.00 - 82.00
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close80.00
  • 52 Week High82.00
  • 52 Week High Date04/24/23
  • 52 Week Low59.00
  • 52 Week Low Date11/24/23

Key Stats

  • Market Cap71.554M
  • Shares Out894,420.03
  • 10 Day Average Volume-
  • Dividend0.50
  • Dividend Yield0.63%
  • Beta-0.36
  • YTD % Change-

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close80.00
  • 52 Week High82.00
  • 52 Week High Date04/24/23
  • 52 Week Low59.00
  • 52 Week Low Date11/24/23
  • Market Cap71.554M
  • Shares Out894,420.03
  • 10 Day Average Volume-
  • Dividend0.50
  • Dividend Yield0.63%
  • Beta-0.36
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-0.51
  • P/E (TTM)-156.33
  • Fwd P/E (NTM)-
  • EBITDA (TTM)1.581M
  • ROE (TTM)-1.17%
  • Revenue (TTM)61.624M
  • Gross Margin (TTM)11.13%
  • Net Margin (TTM)-0.74%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date10/05/2023
  • Div Amount0.50
  • Split Date-
  • Split Factor-

Latest On Bioqual Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Bioqual, Inc. is engaged in performing contract research services, which is focused on in vivo models of human diseases, including COVID-19, acquired immune deficiency syndrome (AIDS), influenza, Mpox, respiratory syncytial virus (RSV) infection, Flavivirus infections, including zika and dengue, malaria, hepatitis, and cancer. It is involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies. The Company also performs in vitro contract...
Mark Lewis Ph.D.
Chairman of the Board, President, Chief Executive Officer
Charles Kirk Jr.
Chief Financial Officer
Chander Sarma
Vice President - Facility Operations, Director - Information Technology
Address
9600 Medical Center Drive, Suite 101
Rockville, MD
20850-3336
United States